Interleukin-3 in the treatment of myelodysplastic syndromes.
Patients with myelodysplastic syndromes frequently present with anemia, leukopenia and thrombocytopenia due to defective maturation of bone marrow cells. Clinical studies with hematopoietic growth factors, including interleukin-3 (IL-3), have been undertaken to evaluate the possibility to reverse cytopenia. In initial phase I/II trials, treatment with IL-3 has resulted in an increase of neutrophil counts in 59%, of platelet counts in 34%, and in reticulocyte counts in 25% of the patients. Adverse effects were rather mild but in individual patients a reversible decrease in platelet counts and in the number of blast cells in blood and bone marrow were observed. Further clinical trials should concentrate on the combination of an early acting cytokine like IL-3 and later acting hemopoietic growth factors like erythropoietin and granulocyte colony-stimulating factor.
Ganser
A
A
Ottmann
O G
OG
Hoelzer
D
D
D004341:Drug Evaluation; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000628:therapy*
D007377:Interleukin-3